Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1001 to 1010 of 2606 total matches.
Quinupristin/Dalfopristin
The Medical Letter on Drugs and Therapeutics • Nov 19, 1999 (Issue 1066)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Quinupristin and dalfopristin, two streptogramin antibacterials marketed in a 30:70 combination as Synercid, have received accelerated approval from the FDA for intravenous treatment of bacteremia and life-threatening infection....
Rivastigmine (Exelon) For Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000 (Issue 1089)
The Medical Letter
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 Main ...
Rivastigmine tartrate (Exelon - Novartis), a carbamate-based cholinesterase inhibitor, is now being marketed for treatment of patients with dementia due to Alzheimer's disease.
OTC loratadine (Claritin)
The Medical Letter on Drugs and Therapeutics • Jan 06, 2003 (Issue 1147)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
The FDA has approved the marketing of loratadine (Claritin - Schering), a second-generation H1-antihistamine, without a prescription. The drug was also recently approved for OTC use as Alavert (Wyeth) and other generics are expected.
Over-the-counter Omeprazole (Prilosec OTC)
The Medical Letter on Drugs and Therapeutics • Aug 04, 2003 (Issue 1162)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
The FDA recently approved the proton pump inhibitor omeprazole magnesium (Prilosec OTC) for over-the-counter use for treatment of frequent heartburn. It will be marketed in late September or early October. Five proton pump inhibitors, including omeprazole, are available by prescription in the US (Medical Letter 2001; 43:36).
Cinacalcet (Sensipar)
The Medical Letter on Drugs and Therapeutics • Sep 20, 2004 (Issue 1192)
Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. 1000 Main Street, New ...
Cinacalcet hydrochloride (Sensipar - Amgen) has been approved by the FDA for treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis and treatment of hypercalcemia in patients with parathyroid carcinoma.
Clarification: Hand Hygiene and CDAD
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007 (Issue 1253)
Letter
®
On Drugs and Therapeutics
Volume 49 (Issue 1253)
January 29, 2007
www.medicalletter.org ...
In the recent Medical Letter article on the treatment of Clostridium difficile–associated disease (CDAD) we wrote: “Healthcare workers caring for patients with C. difficile infection should follow contact isolation precautions, especially use of gloves and hand washing with soap and water after glove removal. Alcohol-based products such as hand sanitizers will not eradicate C. difficile spores.”1 One reader pointed out that alcoholbased products do eradicate some C. difficile spores and have been invaluable against other pathogens.In an unpublished study available as an abstract, both...
In Brief: Toxicity of Gadolinium-Based Contrast Agents
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007 (Issue 1262)
Letter
®
On Drugs and Therapeutics
Volume 49 (Issue 1262)
June 4, 2007
www.medicalletter.org ...
Gadolinium-based contrast agents, which are used mainly for magnetic resonance imaging and angiography, were first introduced partly because of the discovery in the 1990’s that iodine-based contrast agents could cause nephrotoxicity and acute renal failure. Some recent reports have suggested, however, that gadolinium-based agents may also be nephrotoxic.1 One patient who developed acute renal failure after use of gadolinium-based contrast had a renal biopsy that showed acute tubular injury.2Moreover, after exposure to gadolinium-based contrast, some patients with severe renal insufficiency,...
Addendum: Warfarin-Acetaminophen Interaction
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008 (Issue 1288)
Letter
®
On Drugs and Therapeutics
Volume 50 (Issue 1288)
June 16, 2008
www.medicalletter.org ...
A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions”1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect.2Patient susceptibility varies, possibly on a genetic basis; occasional use of acetaminophen generally has little or...
Varenicline (Chantix) Warnings: Risk Versus Benefit
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008 (Issue 1290)
Letter
®
On Drugs and Therapeutics
Varenicline (Chantix) Warnings: Risk
Versus Benefit
Volume 50 ...
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations of preexisting psychiatric illness associated with its use. Agitation, hostility, depressed mood, suicidal ideation and suicidal behavior have been reported as postmarketing adverse events in patients who took varenicline and stopped smoking and in those who took the drug and continued to smoke.
In Brief: Injectable Paliperidone Palmitate for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
The Medical Letter
®
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 ...
Paliperidone palmitate (Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006.1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen.2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal), which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better...